Actelion to host Conference Call / Audiocast on the positive GRIPHON Study Results

Actelion Pharmaceuticals Ltd / Actelion to host Conference Call / Audiocast on the positive GRIPHON Study Results . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Dear member of the investment community,

Actelion Ltd will host a Conference Call / Audiocast on the positive GRIPHON Study Results today, on Monday, 16 June 2014, at 14.00 CEST / 13.00 BST / 08.00 a.m. EDT.

The company announced today that selexipag met the primary endpoint in the pivotal Phase III GRIPHON outcome in patients with pulmonary arterial hypertension.

Actelion will present the top-line results and be available for Q&A.

Management will be represented by:

Jean-Paul Clozel (Chief Executive Officer)Guy Braunstein (Head of Global Clinical Development)Andrew Weiss (Head Investor Relations & Corporate Communications)

 

Date/Time:

16 June 2014 14.00 hrs - 15.00 hrs Basel (CEST)   13.00 hrs - 14.00 hrs UK (BST)   08.00 a.m. - 09.00 a.m. US (EDT)

 

Conference Call Connect #:

Dial-in participants should start calling the number below 10-15 minutes before the conference is due to start.

Dial: Europe: +41 (0) 225 802 991   UK: +44 (0)203 043 24 61   US: +1 866 895 85 61

 

Participant's mode:

Listen-Only with possibility to open individual lines during Q&A session. Participants will be asked for their Name and Company.

Audiocast Access:

Audiocast participants should visit the Actelion website www.actelion.com 10-15 minutes before the conference is due to start.

Participant's mode:

Listen only

 

Audiocast Replay:

The archived Investor Audiocast will be available for replay through http://www.actelion.com approximately 60 minutes after the call has ended.

 

For further information please contact:

Andrew Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications 
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil      
+41 61 565 62 62
http://www.actelion.com

 

Invitation PDF


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Globenewswire
HUG#1793158

--- End of Message ---

Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland

ISIN: CH0010532478;